Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-06266047 · 1 trial · 1 indication
Number of participants with AEs occurring after first dose of study drug. Relatedness to study drug will be assessed by investigator.
Number of subjects with standard safety laboratory test results of potential clinical significance (according to pre-defined criteria).
Absolute values and changes from baseline for the ECG parameters
Absolute values and changes from baseline for blood pressure and pulse rate
All abnormal rhythms will be reviewed by the study physician for the presence of rhythms of potential clinical concern. The time, duration and description of any clinically significant event will be recorded.
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Placebo |
| PF-06266047 | EXPERIMENTAL | PF-06266047 |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Placebo |
| PF-06266047 | DRUG | PF-06266047 |
Inclusion Criteria: 1. Healthy female subjects of non-childbearing potential and/or male subjects who, at the time of screening, are between the ages of 18 and 55 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical exa...
PF-06266047 is an investigational small molecule being studied in healthy volunteers. It is not approved for any disease and is in clinical development to evaluate its safety, tolerability, and pharmacokinetics. The drug is being developed by Pfizer, Inc. (PFE).
PF-06266047 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker PFE. The drug is an investigational small molecule currently in Phase 1 clinical development for use in healthy volunteers.
PF-06266047 is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities. A Phase 1 study has been completed to assess its safety, tolerability, and pharmacokinetics in healthy adult subjects.
PF-06266047 has one completed clinical trial, identified as NCT02539550. This Phase 1 study evaluated the safety, tolerability, and pharmacokinetics of PF-06266047 in healthy adult subjects. The trial was conducted in Belgium with 25 participants and was placebo-controlled and double-blind.
PF-06266047 is not FDA approved. It is an investigational drug in Phase 1 clinical development. The completed trial, NCT02539550, was a Phase 1 study in healthy volunteers, and the drug has not been approved for any medical use.